Galenicum Health obtains approval for Anastrozole in Brazil

June 15, 2018

The Brazilian Health Regulatory Agency (ANVISA) approved Galenicum’s Anastrozole Dossier in the month of May. It is the first product that Galenicum gets approval in Brazil since the opening of its commercial office in 2012. This approval is expected to open the path for further approvals in that market and, what is more, it consolidates Galenicum’s international business.

Anastrozole is an oncological product that inhibits aromatase and eliminates estrogen, thus preventing the growth of breast cancer. For the development of the product, Galenicum has carried out a bioequivalence study vs. the reference product in Brazil obtaining successful results.

 Homo L Gran